Recent Changes in WHO Classification of Digestive Tumors
The most significant recent changes in the WHO classification of digestive tumors are found in the 6th Edition (2026), which introduces major structural reorganization, new tumor entities, simplified grading systems, and refined neuroendocrine neoplasm classification, building upon the foundational changes established in the 5th Edition (2019). 1
Major Structural Changes
Organizational Framework
The 6th edition fundamentally restructures how digestive tumors are classified:
- Epithelial tumors are now organized by anatomical site rather than by tumor type, improving clinical utility 1
- Neuroendocrine, mesenchymal, and hematolymphoid tumors have dedicated separate chapters, aligned with other WHO tumor volumes for consistency 1
- Genetic tumor syndromes are classified by mechanisms, pathways, and genes rather than by clinical presentation 1
- Carcinoma of unknown primary (CUP) receives its own section for the first time, classified by molecular and immunophenotypic profiles to guide therapy 1
Neuroendocrine Neoplasm Classification Evolution
Critical Distinction: NET G3 vs NEC G3
The most clinically impactful change involves recognizing that well-differentiated NET G3 and poorly-differentiated NEC G3 are biologically distinct diseases despite both having Ki-67 >20% 2:
WHO 2017/2019 Classification (Current Standard):
- NET G1: Ki-67 ≤2%
- NET G2: Ki-67 3-20%
- NET G3: Ki-67 >20%, well-differentiated morphology
- NEC G3: Ki-67 >20%, poorly-differentiated morphology
This distinction is crucial because:
- NET G3 tumors harbor DAXX/ATRX/MEN1 mutations and respond poorly to platinum-based chemotherapy but have better survival 2
- NEC G3 tumors show p53 mutation or RB loss and require different therapeutic approaches 2
- Clinical history, histomorphology, and genetics help separate these groups 2
Terminology Updates
- MANEC (Mixed Adenoneuroendocrine Carcinoma) has been replaced by MiNEN (Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm), recognizing that the non-neuroendocrine component may not always be adenocarcinoma 3
- Amphicrine-like carcinoma (ALC) is now distinguished from MiNEN, broadening understanding of tumors with dual neuroendocrine-non-neuroendocrine differentiation 1
- Each component of MiNEN should constitute at least 30% of the tumor for this designation 3
Site-Specific Changes
Gastric Tumors
- Consolidation of gastric dysplasia entities into simplified categories 1
- Oesophageal epidermoid metaplasia introduced as new entity 1
Small Intestinal Tumors
- Duodenal/ampullary tumors are now separated from jejuno-ileal tumors, recognizing distinct biological behavior 1
Colorectal Tumors
Serrated Lesion Nomenclature (Controversial Change):
- The term "sessile serrated lesion" (SSL) replaces "sessile serrated polyp/adenoma" 4
- This remains controversial but aims for uniformity 4
New Entities:
- Colorectal intramucosal adenocarcinoma 1
- Low-grade tubuloglandular adenocarcinoma 1
- Lymphoglandular complex-like adenocarcinoma 1
Grading Changes:
- Novel carcinoma grading system introduced 1
- Grading now based on least differentiated component rather than predominant pattern 3
- Only adenocarcinoma NOS and mucinous adenocarcinoma should be graded; other subtypes have inherent prognostic implications 3
Appendiceal Tumors
Major Reclassification:
- "Goblet cell carcinoid" is now "goblet cell adenocarcinoma", reflecting its aggressive behavior and adenocarcinoma biology 4, 5
- This change has significant therapeutic implications as these tumors require different management than neuroendocrine tumors
Hepatobiliary Tumors
Cholangiocarcinoma:
- Intrahepatic cholangiocarcinoma split into small-duct and large-duct subtypes as separate entities, recognizing distinct molecular profiles and clinical behavior 1
New Hepatocellular Entities:
- Sonic hedgehog hepatocellular adenoma introduced 1
- Intraductal tubulopapillary neoplasm of bile ducts 1
- Intraductal oncocytic papillary neoplasm of bile ducts 1
Undifferentiated Carcinoma:
- Redefined to include "carcinoma with mesenchymal differentiation" 1
Anal Canal
- Terminology harmonized with HPV-related Lower Anogenital Squamous Terminology (LAST) 1
- Mass-forming biliary and gallbladder cancer precursors now share similar terminology 1
Universal Grading System Changes
Two-Tier Grading System
A major theme across the 6th edition is simplification to two-tier (low-grade/high-grade) classification:
- All precursor lesions throughout the GIT now use low-grade vs high-grade dysplasia 4
- This replaces previous three-tier systems and improves reproducibility 3
- Applies uniformly across esophagus, stomach, small intestine, and colorectum 4
Neuroendocrine Tumor Grading
- Enhanced criteria for NET grading with emphasis on both mitotic count (per 2 mm²) and Ki-67 index 2
- When mitotic count and Ki-67 index are discordant, the higher grade must be assigned 2
- Mandatory reporting of both parameters 2
Molecular Integration
Expanded Role of Molecular Pathology
The 6th edition emphasizes molecular characterization:
- Molecular profiles guide CUP classification and therapy selection 1
- Genetic alterations cannot reliably distinguish intrahepatic from extrahepatic cholangiocarcinoma, limiting their diagnostic utility for anatomic classification 6
- Molecular testing increasingly important for prognosis and treatment prediction 5
Risk Factor Documentation
- Routine recording of known risk factors for CCA cases is now recommended to monitor epidemiology 6
- Specify risk factors present or explicitly note absence of known risk factors 6
Clinical Implications
Diagnostic Precision
The 6th edition strengthens diagnostic precision through:
- Clearer morphological criteria
- Integration of molecular features
- Standardized terminology across organ systems 1
Treatment Selection
Changes directly impact therapy:
- NET G3 vs NEC G3 distinction determines chemotherapy regimen (avoid platinum-based for NET G3) 2
- Goblet cell adenocarcinoma requires adenocarcinoma-directed therapy, not NET protocols 4
- CUP molecular classification guides targeted therapy selection 1
Reporting Requirements
Pathologists must now report:
- Both mitotic count and Ki-67 for neuroendocrine neoplasms 2
- Morphological differentiation (well vs poorly) in addition to grade for high-grade tumors 2
- Least differentiated component for colorectal carcinoma grading 3
Common Pitfalls to Avoid
- Do not call NET G3 tumors "neuroendocrine carcinomas" - they are biologically distinct despite high Ki-67 2
- Do not grade all colorectal adenocarcinoma subtypes - only NOS and mucinous types should be graded 3
- Do not use "goblet cell carcinoid" terminology - these are adenocarcinomas 4
- Do not rely solely on Ki-67 for NET vs NEC distinction - morphology and genetics are essential 2
- Do not use three-tier dysplasia grading - all GIT dysplasia is now low or high grade 4